1 / 10

SMC RESPONSE TO EVALUATION

Angela Timoney Vice Chair SMC 23 rd September 2008. SMC RESPONSE TO EVALUATION. SMC response to phase one of SMC Evaluation.

nassor
Download Presentation

SMC RESPONSE TO EVALUATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Angela Timoney Vice Chair SMC 23rd September 2008 SMC RESPONSE TO EVALUATION

  2. SMC response to phase one of SMC Evaluation • SMC will continue to support the SMC Patient and Public Involvement group’s (PAPIG) aim of achieving more effective understanding of and public engagement with SMC processes and outputs. 2. SMC will continue to support PAPIG's aim of improving the support and feedback given to Public Partners contributing to a new medicine evaluation.

  3. SMC will work with PAPIG to determine the need and feasibility of developing the current media brief for use as a lay patient and public brief.

  4. SMC will continue to work with the Pharmaceutical Industry to ensure timely submissions for new medicines to meet the SMC aim of providing advice to NHS Boards within three months of UK availability of the medicine.

  5. SMC will explore with the SMC Industry user group further refinements to the submission process and effective engagement with manufacturers through that process.

  6. SMC will work with the pharmaceutical industry and NHS Boards, to enable consistency in the standard and presentation of budget impact information provided by the pharmaceutical industry for new medicines and to maximise the usefulness of the resultant estimates.

  7. SMC will develop a programme to support engagement with the wider clinical community and develop understanding of SMC processes. This will include:- a. Chairman / Exec team members visiting all ADTCs across Scotland to update committees on the work to date and obtain feedback from ADTC members b. Holding a conference in September reporting results of the evaluation to which all ADTC members will be invited c. Discussing with ADTCs and NHS Boards ways to identify those individuals likely to be potential future members of SMC and its subcommittees and to develop their relevant skills d. Work with others to support prescribers in the understanding and implementation of SMC advice

  8. SMC will explore mechanisms to achieve more effective engagement with relevant clinical specialities and sub-specialities in its review process and develop standards for engagement with experts.

  9. 9. SMC will consolidate existing work with agencies such as the Information Services Division (ISD) and NHS National Services Scotland (NSS) to explore the feasibility and benefit of   routinely monitoring the uptake of SMC advice and the publication of this information regularly to interested stakeholders. This will be dependant on the availability of improved information to NHS Scotland on the prescribing and use of medicines in secondary care. • SMC will continue to work with ISD to develop systems to assess uptake of new medicines. A priority may be the medicines that were included in the ‘Forward Look’ (SMC horizon scanning report) and have subsequently been accepted by SMC, seeking to learn lessons to inform future horizon-scanning work. This will be dependant on availability of improved information to NHS Scotland on the prescribing and use of medicines in secondary care.

  10. Thank you

More Related